

BSE SENSEX 81,119
S&P CNX 24,719



Stock Info

Bloomberg	UTIAM IN
Equity Shares (m)	128
M.Cap.(INRb)/(USD\$)	157.4 / 1.8
52-Week Range (INR)	1408 / 905
1, 6, 12 Rel. Per (%)	16/-9/19
12M Avg Val (INR M)	335
Free float (%)	100.0

Financials Snapshot (INR b)

Y/E March	2025	2026E	2027E
AAUM	3,363	3,888	4,576
MF Yield (bps)	34.2	33.2	32.2
Rev from Ops	14.5	16.2	18.5
Core PAT	4.9	5.9	7.1
PAT	8.1	9.1	10.5
PAT (bps as AAUM)	24	23	23
Core EPS	39	46	56
EPS	64	71	82
EPS Grw. (%)	1	12	16
BVPS	405	427	452
RoE (%)	16	17	19
Div. Payout (%)	74	70	70

Valuations


Mcap/AUM (%)	4.6	4.0	3.4
P/E (x)	19.2	17.2	14.9
P/BV (x)	3.0	2.9	2.7
Div. Yield (%)	3.9	4.0	4.7

Shareholding Pattern (%)

As On	Mar-25	Dec-24	Mar-24
Promoter	0.0	0.0	0.0
DII	59.7	59.3	60.9
FII	7.9	7.9	6.0
Others	32.4	32.9	33.1

FII includes depository receipts

Stock Performance (one-year)



CMP: INR1,230

TP: INR1,550 (+26%)

Buy

Strong fund performance to revive market share

SIPs continue to scale up; least re-rated stock in the universe

- UTI AMC's fund performance over the past five months has improved considerably, with an average of ~70% equity AUM appearing in Q1 and Q2 on a one-year return basis in May'25 vs an average of 25% in the preceding 12 months. This, we believe, can drive equity market share gains, which have been stable at 3.9% over the past seven months.
- Recent product launches (Quant Fund launched in Q4FY25 and Multi-Cap Fund in Apr'25) are likely to support equity inflows. Ongoing traction in hybrid funds and the rollout of smart beta and thematic offerings further enhance UTI AMC's positioning across investor segments.
- UTI AMC's SIP AUM grew 22% YoY to INR375.9b, supported by increased investor engagement through MFDs and direct platforms. Despite weaker markets, SIP inflows in FY25 rose 23% YoY to INR83.3b. Notably, 47.9% of equity/hybrid gross sales were mobilized through digital platforms in Q4FY25, reflecting the success of platform integration and marketing automation.
- UTI AMC continues to deepen penetration in B30 cities, with 22% of monthly average AUM in Mar'25 originating from these regions—outperforming the industry average of ~18%. The company added 68 branches in Tier-2 and Tier-3 locations during FY25, driving incremental folio growth (0.9m net folio additions in FY25).
- Overall yields stood at ~34bp in Q4FY25. While equity and hybrid funds earned ~75bp, a growing share of passive flows (ETF/index funds at 5–6bp yield) is expected to lead to a slight yield contraction (1-2bp), partially cushioned by distributor commission rationalization.
- We expect UTI AMC to report AUM/Revenue/Core PAT CAGR of 17%/13%/20% over FY25-27. Sustained strong performance has been a key re-rating driver for AMC stocks. UTI AMC's discount to other players has widened over the past few months. We reiterate our BUY rating on UTI AMC with a one-year TP of INR1,550, based on 19x FY27E EPS (28x Core EPS).


Fund performance sees significant improvement based on one-year returns

- **As a % of Monthly Average AUM (MAUM):** The share of AUM ranked in the top quartile (one-year returns) rose sharply to 48% in May'25, up from just 12% in May'21. Conversely, the proportion of AUM in the top quartile based on three-year returns declined to 8% from 38% over the same period.
- **Based on the number of schemes:** The number of schemes ranked in the top quartile (one-year return) improved significantly to 6 in May'25 from 2 in May'21. For three-year returns, the number of top-quartile schemes rose modestly to 3 from 2 over the same period, indicating an overall positive trend in performance.

Equity segment: Better fund performance and new product launches being key growth drivers


- Equity QAAUM grew 7.2% YoY to INR908.6b, with net sales turning positive at INR13b in 4QFY25, compared to net outflows of INR13.4b in 4QFY24. However, on a yearly basis, net outflow stood at INR19.2b, reducing YoY from INR56.7b in FY24.
- The equity market share declined to 3.1% in 4QFY25 vs 3.7% in 4QFY24 and 3.2% in 3QFY25. However, with improving fund performance (57% of equity AUM in the top two quartiles over the past year), the launch of new funds (BAF launched in Jul'23, multi-cap in FY25, Quant Fund in 4QFY25) and the scaling up of SIPs through digital partnerships are expected to support growth in equity AUM, thus leading to higher market share for UTI AMC.

Exhibit 1: QAAUM mix (%)




Source: MOFSL, Company

Exhibit 2: Equity AUM continues to trend upwards




Source: MOFSL, Company

Exhibit 3: Net sales turned positive in FY25




Source: MOFSL, Company

Exhibit 4: Market share has stabilized over the last few months despite the fall from the peak




Source: MOFSL, Company

Exhibit 5: MFD channel continues to dominate




Source: MOFSL, Company

Exhibit 6: Equity inflows expected to rise with improving fund performance (based on the number of schemes)




Source: MOFSL, Company

Exhibit 7: Based on one-year return, proportion (%) of AUM appearing in Quartile 1 and Quartile 2



Source: MOFSL, Company

Exhibit 8: Based on three-year return, proportion of AUM (%) appearing in Quartile 1 and Quartile 2




Source: MOFSL, Company


Strong growth in AUM driven by passive flows

- UTI AMC's AUM growth trajectory continues to be driven by its leadership in the passive investment segment.
- UTI AMC's MF QAAUM reached INR3.4t, up 16.8% YoY, with passive assets (ETFs and index funds) contributing INR1.4t in 4QFY25 (23% YoY). This surge in passive AUM is underpinned by: 1) strong growth in ETFs and index flows by 14%/68% YoY in 4QFY25/FY25 to INR36.8b/INR196.1b, 2) UTI's strong foothold in managing EPFO flows, 3) broader shift of demand toward low-cost index products, and 4) launch of innovative product offerings in the segment.


- On the product front, in FY25, UTI AMC further expanded its passive product suite by launching three smart beta funds, two thematic index funds, and one market cap-based index fund. Management has also indicated plans for additional launches in the ETF and index fund segment going forward.
- Over the long term, the shift toward passives, rising institutional demand, and UTI AMC's competitive positioning in EPFO mandates are expected to continue driving the company's AUM growth.

Exhibit 9: Passives stood at 34% in the QAAUM mix



Source: MOFSL, Company

Exhibit 10: Index and ETFs AUM growth led by robust flows


Source: MOFSL, Company

Exhibit 11: Net sales rose in FY25


Source: MOFSL, Company

Exhibit 12: Market share improves



Source: MOFSL, Company

Expanding digital distribution and B30 presence

- Digital transformation has been a core growth pillar for UTI AMC. The company has enhanced distributor engagement via tools like 'UTI Buddy' and integrated all digital assets under 'UTI HART'.
- ~47.87% of total gross sales of Equity & Hybrid Funds were mobilized through Digital Platforms in Q4FY25. There was a 25% YoY growth in the number of digital SIP transactions in Q4FY25 compared to Q4FY24.
- UTI AMC became the first mutual fund house to leverage salesforce's marketing automation and personalization capabilities, enabling effective cross-selling and upselling. This strategic move has significantly contributed to the growth of online gross sales.
- Moreover, its B30 segment penetration improved, with 22% of its monthly average AUM in Mar'25 coming from beyond the top 30 cities—above the industry average of 18%. Of the total 255 UTI financial centers, 205 were located in B30 cities as of Mar'25 (68 were opened in FY25).

Exhibit 13: 95.1% of gross sales are done via online mode


■ Online gross sales as % of total gross sales



Source: MOFSL, Company

Exhibit 14: Digital purchase transactions are starting to see an uptick


■ Number of digital purchase transactions



Source: MOFSL, Company

Exhibit 15: Gross sales on an uptick


■ % of Equity + Hybrid MF gross sales through digital platform



Source: MOFSL, Company

Exhibit 16: UTI AMC outperforms industry growth based on MAAUM in B30 cities

■ UTI AMC (%) ■ Industry (%)



Source: MOFSL, Company

International business: Spreading across geographies

- UTI International, managing offshore funds, reported a 10% YoY revenue growth in FY25 to INR1.4b, contributing ~12% to UTI AMC's total revenue for the year.
- It manages an AUM size of INR253.8b as of Mar'25, reflecting a decline of 8% YoY and 13% QoQ, primarily due to MTM losses in its two key funds—UTI Innovation Fund and UTI Dynamic Fund. However, the company anticipates a recovery driven by growing engagement from institutional investors.
- It operates with a 30-member team spread across Singapore, Dubai, London, New York, and Paris (recently secured regulatory approval).
- UTI International upgraded its regulatory license with the Dubai International Financial Centre (DIFC) to enhance its investment advisory capabilities in the Middle East.
- Though initial international expansion costs may elevate operating expenses, the growing global footprint and rising yields position this vertical as a meaningful contributor to medium-term growth.

Exhibit 17: Trend in QAAUM





Exhibit 18: Revenue trends upward



Dominant in the NPS industry

- Revenue from the NPS segment stood at INR 350m in 4QFY25 (+13% YoY) and INR1.4b in FY25 (+15% YoY), contributing 12% to UTI AMC's overall revenue in FY25.
- The NPS ecosystem continued to witness strong growth, with total AUM reaching INR3.6t as of Mar'25, registering a 19% YoY increase. UTI Pension Fund managed 24.86% of the industry's AUM.
- The private sector NPS segment remained a key growth driver, with AUM rising 61% YoY, indicating strong traction among retail and corporate investors.
- The company is actively expanding its Point of Presence (POP) operations. Headcount rose by ~40 in FY25, with management guiding for a similar hiring pace in the near term to support growth initiatives.
- During 4QFY25, the Competent Authorities of PFRDA approved the transfer of all schemes managed by Max Life Pension Fund to UTI Pension Fund, reflecting the latter's superior fund performance.
- UTI Pension Fund Limited (UTI PFL) is now fully operational across 21 locations pan-India, strengthening its physical distribution footprint.

Exhibit 19: Trend in UTI PFL AUM






Exhibit 20: Revenue trending upwards



Source: MOFSL, Company

Exhibit 21: Market share trends




Source: MOFSL, Company

UTI alternatives: Strategic focus on diversifying its investment offerings


- Revenue from operations grew 64% YoY to INR154m in FY25, while PAT declined 79% YoY to INR9m on account of MTM losses and currency fluctuations.
- UTI Alternatives Ltd. registered under UTI Alternatives Private Ltd. had a total AUM of INR26.5b as of Mar'25 (34% YoY growth).
- UTI's first Structured Debt Opportunities Fund (SDOF) successfully exited all investments with profits, while SDOF 2 has a net commitment of INR2.4b and is currently in an exit mode. UTI SDOF 3 has a net commitment of INR6.2b and is in the fundraising and investing stage.
- UTI Multi Opportunities Fund I is also currently in the investing stage and has net commitments of INR16b. The UTI Real Estate Opportunities Fund I is currently in fundraising mode with a commitment of INR1.5b. Additionally, the UTI Credit Opportunities Fund I and UTI Asset Reconstruction Opportunities Fund are in the investing stage.
- The segment's development aligns with UTI AMC's broader strategy to diversify its asset management offerings and cater to a wider range of investor needs. The alternatives business is expected to become a core profit contributor in the upcoming financial year, supported by ongoing fundraising activities and the launch of new investment products.

Exhibit 22: Trend in alternatives AUM



Source: MOFSL, Company

Exhibit 23: Revenue trending upward



Source: MOFSL, Company


Commission rationalization to partially cushion the equity yield decline

- In Q4FY25, UTI AMC reported a weighted average realization of ~34bp across its asset base. The equity and hybrid categories continued to be the primary yield drivers, generating ~75bp, while ETFs and index funds realized ~5-6bp. The yield on cash and liquid strategies stood at ~9-10bp, and income (debt) funds yielded ~22-23bp.
- Going forward, management has guided for a marginal moderation of 1-2bp in overall yields, primarily due to an increasing share of flows into low-yielding passive products, particularly ETFs and index funds.
- However, this yield contraction is expected to be partially offset by the rationalization of distributor commissions. These efforts are aimed at preserving core profitability metrics despite an evolving asset mix.
- While passive strategies are gaining traction, UTI AMC remains focused on maintaining yield resilience.

Valuation and view

- Equity segment yields are expected to moderate due to the telescopic TER structure; however, the recent commission rationalization is likely to cushion the impact of this dilution. Improving fund performance and scaling up non-MF business will improve profitability over the medium term.
- We expect UTI to report AUM/Revenue/Core PAT CAGR of 17%/13%/20% over FY25-27. Sustained strong performance has been a key re-rating driver for AMC stocks. UTI's discount to other players has widened over the past few months. We reiterate our BUY rating on UTI AMC with a one-year TP of INR1,550 based on 19x FY27E EPS (28x Core EPS).


Exhibit 24: Least re-rated stock in the universe (Rebased one-year forward P/E)



Source: MOFSL, Bloomberg


Story in charts

Exhibit 25: QAAUM mix (%)




Source: MOFSL, Company

Exhibit 26: Trend in SIP AUM




Source: MOFSL, Company

Exhibit 27: SIP flows trend upwards despite weak markets




Source: MOFSL, Company

Exhibit 28: Revenue continues to trend upwards




Source: MOFSL, Company

Exhibit 29: EBITDA margins continue to trend upwards




Source: MOFSL, Company

Exhibit 30: Trend in CIR




Source: MOFSL, Company

Exhibit 31: Trend in consolidated PAT in INRm




Source: MOFSL, Company

Exhibit 32: Trend in Core Profits in INRm




Source: MOFSL, Company

Exhibit 33: Asset-light business model driving high ROE (%)



Source: MOFSL, Company

Exhibit 34: One-year forward P/E



Source: MOFSL, Company

Financials and valuations

Income Statement							INR m	
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E
Investment management fees	7,879	8,066	11,189	11,314	11,821	14,453	16,218	18,530
Change (%)	-11.5	2.4	38.7	1.1	4.5	22.3	12.2	14.3
Operating Expenses	5,057	5,253	6,211	6,550	7,036	7,495	7,987	8,689
Core Operating Profits	2,822	2,812	4,978	4,764	4,785	6,958	8,231	9,841
Change (%)	-16.6	-0.3	77.0	-4.3	0.4	45.4	18.3	19.6
Dep/Interest/Provisions	398	438	460	495	535	583	619	658
Core PBT	2,424	2,374	4,518	4,269	4,250	6,375	7,613	9,183
Change (%)	-19.5	-2.1	90.3	-5.5	-0.5	50.0	19.4	20.6
Other Income	1,031	3,663	2,084	1,587	5,619	4,146	4,169	4,441
PBT	3,454	6,036	6,602	5,856	9,868	10,522	11,782	13,623
Change (%)	-29.7	74.7	9.4	-11.3	68.5	6.6	12.0	15.6
Tax	690	1,087	1,257	1,459	1,848	2,392	2,710	3,133
Tax Rate (%)	20.0	18.0	19.0	24.9	18.7	22.7	23.0	23.0
PAT before non-controlling interest	2,765	4,949	5,346	4,397	8,020	8,130	9,072	10,490
Change (%)	-20.5	79.0	8.0	-17.7	82.4	1.4	11.6	15.6
Less: Non-controlling interest	35	0	0	0	0	0	0	0
PAT	2,730	4,949	5,346	4,397	8,020	8,130	9,072	10,490
Change (%)	-22.6	81.3	8.0	-17.7	82.4	1.4	11.6	15.6
Core PAT	1,905	1,946	3,658	3,206	3,454	4,926	5,862	7,071
Change (%)	-12.6	2.1	88.0	-12.4	7.7	42.6	19.0	20.6
Dividend (incl. tax)	888	2,155	2,666	2,794	5,983	6,143	6,350	7,343

Balance Sheet							INR m	
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E
Equity Share Capital	1,268	1,268	1,270	1,270	1,273	1,280	1,280	1,280
Reserves & Surplus	26,465	31,102	34,907	37,409	48,460	50,324	53,045	56,192
Net Worth	27,733	32,370	36,177	38,678	49,732	51,603	54,325	57,472
Borrowings	0	0	0	0	0	0	0	0
Other Liabilities	3,816	4,279	3,701	3,071	3,678	4,981	5,465	6,128
Total Liabilities	31,549	36,649	39,877	41,749	53,411	56,584	59,790	63,600
Cash and Investments	24,857	29,631	33,862	36,143	48,744	51,843	54,620	57,823
Change (%)	3.7	19.2	14.3	6.7	34.9	6.4	5.4	5.9
Loans	374	252	136	115	86	74	83	95
Change (%)	32.9	-32.8	-46.0	-15.7	-25.0	-14.0	12.2	14.3
Net Fixed Assets	3,529	3,545	3,560	3,683	2,886	2,971	3,184	3,508
Net Current Assets	2,789	3,221	2,320	1,809	1,694	1,696	1,903	2,174
Total Assets	31,549	36,649	39,877	41,749	53,410	56,584	59,790	63,600

E: MOFSL Estimates

							(INR m)	
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E
AAAUM (INR B)	1,552	1,593	2,112	2,344	2,699	3,363	3,888	4,576
Change (%)	-2.5	2.6	32.6	11.0	15.1	24.6	15.6	17.7
Equity (Including Hybrid)	34.3	34.9	38.7	37.2	34.6	34.0	33.0	33.1
Debt	18.0	17.3	12.9	7.5	7.1	6.5	6.3	6.0
Liquid	28.7	22.6	18.5	19.4	17.3	14.6	14.2	13.5
Others	18.9	25.2	30.0	35.8	41.0	44.9	46.6	47.5

E: MOFSL Estimates

Financials and valuations

CashFlow Statement							INR m	
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E
Cash flow from operations	2,922	5,879	6,110	4,803	8,832	9,187	9,863	11,412
PBT	3,454	6,036	6,602	5,856	9,868	10,522	11,782	13,623
Depreciation and amortization	313	358	368	399	423	455	492	531
Tax Paid	(690)	(1,087)	(1,257)	(1,459)	(1,848)	(2,392)	(2,710)	(3,133)
Deferred tax	83	519	(723)	(134)	255	295	(70)	(63)
Interest, dividend income (post-tax)	(144)	(74)	(79)	(178)	(281)	(317)	-	-
Interest expense (post-tax)	68	66	74	72	92	98	98	98
Working capital	(163)	61	1,123	246	324	526	272	356
Cash from investments	(1,362)	(4,347)	(2,464)	(3,112)	(12,316)	(1,377)	(3,035)	(4,156)
Capex	(434)	(374)	(383)	(522)	374	(541)	(705)	(855)
Interest, dividend income (post-tax)	144	74	79	178	281	317	-	-
Investments	(1,073)	(4,047)	(2,160)	(2,768)	(12,972)	(1,154)	(2,330)	(3,301)
Cash from financing	(1,609)	(665)	(1,722)	(2,102)	3,112	(5,965)	(6,301)	(7,248)
Equity	(264)	3	4	(114)	5,854	(232)	-	-
Debt	(93)	(286)	(108)	(134)	170	392	147	193
Interest costs	(68)	(66)	(74)	(72)	(92)	(98)	(98)	(98)
Dividend paid	(888)	(2,155)	(2,666)	(2,794)	(5,983)	(6,143)	(6,350)	(7,343)
Others	(296)	1,840	1,123	1,012	3,163	116	-	-
Change of cash	(49)	867	1,924	(411)	(372)	1,845	527	8
Cash start	1,242	1,193	2,060	3,983	3,572	3,200	5,045	5,572
Cash end	1,193	2,060	3,983	3,572	3,200	5,045	5,572	5,579
FCFF	2,488	5,505	5,727	4,280	9,206	8,646	9,158	10,557

Valuations	2020	2021	2022	2023	2024	2025	2026E	2027E
BVPS (INR)	218	254	284	304	391	405	427	452
Change (%)	5.0	16.7	11.8	6.9	28.6	3.8	5.3	5.8
Price-BV (x)	5.6	4.8	4.3	4.0	3.1	3.0	2.9	2.7
EPS (INR)	21.7	38.9	42.0	34.5	63.0	63.9	71.3	82.4
Change (%)	-20.5	79.0	8.0	-17.7	82.4	1.4	11.6	15.6
Price-Earnings (x)	56.5	31.6	29.2	35.5	19.5	19.2	17.2	14.9
Core EPS (INR)	15.0	15.3	28.7	25.2	27.1	38.7	46.0	55.5
Change (%)	-12.6	2.1	88.0	-12.4	7.7	42.6	19.0	20.6
Core Price-Earnings (x)	82.0	80.3	42.7	48.8	45.3	31.7	26.7	22.1
DPS (INR)	7.0	17.0	21.0	22.0	47.0	48.0	49.6	57.4
Dividend Yield (%)	0.6	1.4	1.7	1.8	3.8	3.9	4.0	4.7

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.